Topokine Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers
Phase 1
Completed
- Conditions
- Nasolabial FoldsLipoatrophyLipodystrophy
- Interventions
- Drug: TAT4 Gel concentration ADrug: TAT4 Gel concentration BDrug: Placebo
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- Topokine Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02647853
- Locations
- 🇺🇸
Topokine Clinical Site, Cypress, California, United States
Live Validation of the Lower Eyelid Steatoblepharon Severity (LESS) Scale
Completed
- Conditions
- Steatoblepharon
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- Topokine Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT02609763
Phase 2 Study of TAT4 Gel for Reduction of Nasolabial Folds
Phase 2
- Conditions
- Nasolabial Folds
- Interventions
- Drug: TAT4 GelDrug: Matching placebo
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Topokine Therapeutics, Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT02607670
- Locations
- 🇺🇸
Topokine Research Site, Boston, Massachusetts, United States
Phase 2b/3 Study of XAF5 Ointment for Steatoblepharon (Undereye Bags)
Phase 2
Completed
- Conditions
- Steatoblepharon
- Interventions
- Drug: Matching placebo
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2017-11-08
- Lead Sponsor
- Topokine Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT02607683
- Locations
- 🇺🇸
David Wirta, MD, Inc., Newport Beach, California, United States
🇺🇸Danbury Eye Physicians, Danbury, Connecticut, United States
🇺🇸South Shore Eye Care, Inc., Wantagh, New York, United States
Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)
Phase 2
Completed
- Conditions
- Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
- Interventions
- Drug: PlaceboDrug: XOPH5 Ointment
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Topokine Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT02230761
- Locations
- 🇺🇸
Topokine Therapeutics Clinical Study Centers, Boston, Massachusetts, United States
Safety and Feasibility Study of XAF5 Gel for Reduction of Submental Fat
Phase 2
Suspended
- Conditions
- Excess Submental Fat ("Double Chin")
- Interventions
- Drug: XAF5 GelDrug: Placebo Gel
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2016-02-29
- Lead Sponsor
- Topokine Therapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT01990326
Phase 1 Study of XAF5 Gel Applied to Skin of Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: XAF5, concentration ADrug: XAF5, concentration BDrug: XAF5, concentration C
- First Posted Date
- 2012-11-07
- Last Posted Date
- 2016-01-12
- Lead Sponsor
- Topokine Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01723241
© Copyright 2025. All Rights Reserved by MedPath